← Back to Search

μCor for Heart Failure (BMAD-TX Trial)

N/A
Waitlist Available
Research Sponsored by Zoll Medical Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 2.5 years.
Awards & highlights

BMAD-TX Trial Summary

This trial is testing how well a new system, which includes a sensor and wearable patch, helps manage heart failure.

BMAD-TX Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 2.5 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2.5 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Investigator Engagement of Device Data
Secondary outcome measures
Correlations of cardiac rhythm μCor measurements and heart failure related symptoms.
Correlations of cardiac rhythm μCor measurements to heart failure related clinical events.
Correlations of respiration rate μCor measurements and heart failure related symptoms.
+15 more

BMAD-TX Trial Design

1Treatment groups
Experimental Treatment
Group I: Device Data Engagement AssessmentExperimental Treatment1 Intervention
This arm will assess the endpoints of investigator engagement with the device data.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
μCor
2019
N/A
~270

Find a Location

Who is running the clinical trial?

Zoll Medical CorporationLead Sponsor
41 Previous Clinical Trials
21,714 Total Patients Enrolled
13 Trials studying Heart Failure
3,501 Patients Enrolled for Heart Failure
Mike OszStudy DirectorZoll Medical Corporation
3 Previous Clinical Trials
733 Total Patients Enrolled
3 Trials studying Heart Failure
733 Patients Enrolled for Heart Failure

Media Library

μCor Clinical Trial Eligibility Overview. Trial Name: NCT04096040 — N/A
Heart Failure Research Study Groups: Device Data Engagement Assessment
Heart Failure Clinical Trial 2023: μCor Highlights & Side Effects. Trial Name: NCT04096040 — N/A
μCor 2023 Treatment Timeline for Medical Study. Trial Name: NCT04096040 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study actively seeking participants at this time?

"Per clinicaltrials.gov, this research is not currently registering volunteers for participation. Originally posted on November 1st 2019 and updated most recently on July 8th 2022, the study has closed its recruitment period; however there are 701 other trials requiring participants at this time."

Answered by AI

Are there various medical facilities conducting this experiment within the state?

"Patient recruitment for this clinical trial is taking place at Jersey Shore University Medical Center, INTEGRIS Baptist Medical Centre in Oklahoma City, and Mission Research Institute located in New Braunfels. Additionally, there are 60 other sites enrolling patients."

Answered by AI

Who else is applying?

What state do they live in?
Iowa
What site did they apply to?
Quincy Medical Group
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Benefits of Microcor in Ambulatory Decompensated Heart Failure
2019. "Benefits of Microcor in Ambulatory Decompensated Heart Failure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04096040.
~48 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top